EMERYVILLE, Calif., July 18, 2026
4D Molecular Therapeutics (4DMT) announced positive two-year results from its PRISM Phase 2b clinical trial evaluating 4D-150, an investigational intravitreal gene therapy for wet age-related macular degeneration (wet AMD). The findings, presented at the 44th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS), demonstrated that a single intravitreal administration of 4D-150 maintained visual acuity, preserved retinal anatomy, and delivered a durable reduction in treatment burden through two years of follow-up. The investigational therapy also continued to show a favorable safety profile, with no new cases of intraocular inflammation or other significant ocular safety concerns after the initial monitoring period. These results further support the ongoing Phase 3 development of 4D-150 as a potential long-term treatment option for patients with wet AMD.
Advanced Wound Sealant Delivers Long-Lasting Incision Protection
The PRISM Phase 2b trial enrolled 45 patients across two dose levels of 4D-150, with the 3E10 vg/eye dose selected for the ongoing 4FRONT Phase 3 clinical program. Throughout the two-year follow-up, patients maintained best corrected visual acuity (BCVA) and central subfield thickness (CST), indicating sustained disease control after only one intravitreal injection. The therapy also achieved a 78% reduction in overall anti-VEGF treatment burden across the entire study population, requiring an average of only 2.7 supplemental injections compared with the projected 12 injections associated with standard aflibercept treatment. Among recently diagnosed patients, treatment burden was reduced by 87%, with patients requiring an average of only 1.6 supplemental injections, highlighting the potential of 4D-150 to substantially reduce the frequency of ongoing retinal injections while maintaining vision.
Long-Term Safety Supports Continued Phase 3 Development
The updated safety analysis included 71 patients treated with the Phase 3 dose across the PRISM Phase 1/2a and Phase 2b clinical trials. 4D-150 continued to demonstrate excellent long-term tolerability, with only 2.8% of patients experiencing mild, transient intraocular inflammation during approximately the first six months after treatment. Importantly, no additional inflammation cases were observed during follow-up extending from two to more than four years after dosing. Investigators also reported no treatment-related hypotony, endophthalmitis, retinal vasculitis, occlusive or non-occlusive retinal vasculitis, choroidal effusions, or other serious ocular safety events, reinforcing the therapy’s favorable safety profile as clinical development advances toward regulatory evaluation.
Advertisement
4D-150 Aims to Transform Wet AMD Treatment Paradigm
4D-150 is designed to become a foundational backbone therapy for wet AMD by providing multi-year, potentially lifelong delivery of anti-VEGF biologics following a single intravitreal injection. The investigational therapy utilizes 4DMT’s proprietary R100 intravitreal AAV vector to continuously express aflibercept together with anti-VEGF-C, targeting abnormal blood vessel growth responsible for progressive retinal damage. The program is also being developed for diabetic macular edema (DME), another major retinal vascular disease requiring frequent injections. Positive two-year PRISM results strengthen confidence in the ongoing 4FRONT Phase 3 clinical trials, supporting the potential for 4D-150 to significantly reduce treatment burden while preserving long-term vision for millions of patients affected by retinal vascular diseases worldwide.
Source: 4DMT press release
